David A. Siegel Ventyx Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 213,000 shares of VTYX stock, worth $477,120. This represents 0.0% of its overall portfolio holdings.
Number of Shares
213,000
Previous 88,400
140.95%
Holding current value
$477,120
Previous $486,000
1.23%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding VTYX
# of Institutions
123Shares Held
57.5MCall Options Held
222KPut Options Held
269K-
Deerfield Management Company, L.P. (Series C) New York, NY5.83MShares$13.1 Million0.28% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il5.76MShares$12.9 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA5.25MShares$11.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$10.7 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.1 Million0.04% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $127M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...